Are you Dr. Molnar?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 31 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
S Hawthorne Rd
Winston Salem, NC 27157Phone+1 336-716-2255
Summary
- Dr. Istvan Molnar, MD is an oncologist in Winston Salem, North Carolina. He is currently licensed to practice medicine in North Carolina.
Education & Training
Wake Forest University Baptist Medical CenterFellowship, Hematology and Medical Oncology, 2000 - 2002
University of Oklahoma Health Sciences CenterFellowship, Hematology and Medical Oncology, 1995 - 1996
Huron HospitalResidency, Internal Medicine, 1992 - 1995
Semmelweis UniversityClass of 1991
Certifications & Licensure
NC State Medical License 2000 - 2016
Clinical Trials
- Cholecalciferol in Treating Patients With Myelodysplastic Syndrome Start of enrollment: 2003 Jul 01
- Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment Start of enrollment: 2003 May 01
- Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes Start of enrollment: 2004 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 20 citationsAntifungal and Cytotoxic β-Resorcylic Acid Lactones from a Paecilomyces SpeciesLiangxiong Xu, Ping Wu, Jinghua Xue, István Molnár, Xiaoyi Wei
Journal of Natural Products. 2017-07-27 - 22 citationsBio-crude transcriptomics: gene discovery and metabolic network reconstruction for the biosynthesis of the terpenome of the hydrocarbon oil-producing green alga, Botry...István Molnár, David Lopez, Jennifer H. Wisecaver, Timothy P. Devarenne, Taylor L. Weiss
BMC Genomics. 2012-10-30 - 9 citationsNovel innate cancer killing activity in humansMichael J Blanks, John R. Stehle, Wei Du, Jonathan M Adams, Mark C. Willingham
Cancer Cell International. 2011-08-03
Press Mentions
Radionetics Oncology Appoints Istvan Molnar, M.D. As Chief Medical OfficerFebruary 22nd, 2023- Lantheus Announces Presentation Featuring AZEDRA® (Iobenguane I 131) at ENDO 2021March 22nd, 2021
- Lantheus Holdings Announces Acceptance and Priority Review of New Drug Application for PyLTM (18F-DCFPyL), a PSMA-Targeted Prostate Cancer PET Imaging AgentDecember 9th, 2020
- Join now to see all
